A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK-8353 (Formerly SCH 900353) in Subjects With Advanced Solid Tumors (Protocol No. 001 (Formerly P06203)).

Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK-8353 (Formerly SCH 900353) in Subjects With Advanced Solid Tumors (Protocol No. 001 (Formerly P06203)).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2014

At a glance

  • Drugs MK 8353 (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 30 Jun 2014 According to the ClinicalTrials.gov record, status changed from recruiting to discontinued.
    • 03 Sep 2013 Planned end date changed from 1 Jun 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
    • 31 May 2013 Planned number of patients changed from 99 to 117 as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top